Physicians' Academy for Cardiovascular Education

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD - Leiden, The Netherlands

Video navigation menu

  • TG and CV risk 0:21
  • CV outcome trials with icosapent ethyl 2:34
  • Identifying the right patients 5:10
  • Remaining questions 6:44
  • Take-home message 8:53

Do you prescribe icosapent ethyl to patients with residual CV risk based on the findings from REDUCE-IT?

  • Yes
  • No


Show transcript

Educational information

This presentation by Wouter Jukema is part of a series titled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".


Prof. J. Wouter Jukema, MD is Professor of Cardiology at the Leiden University Medical Center in Leiden, The Netherlands.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

Find all videos of this series in the meeting report Listen to the podcast

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: